CA3169702A1 - Methods and compositions for treating or preventing an inflammatory condition - Google Patents
Methods and compositions for treating or preventing an inflammatory condition Download PDFInfo
- Publication number
- CA3169702A1 CA3169702A1 CA3169702A CA3169702A CA3169702A1 CA 3169702 A1 CA3169702 A1 CA 3169702A1 CA 3169702 A CA3169702 A CA 3169702A CA 3169702 A CA3169702 A CA 3169702A CA 3169702 A1 CA3169702 A1 CA 3169702A1
- Authority
- CA
- Canada
- Prior art keywords
- cbd
- hydroxychloroquine
- pharmaceutically acceptable
- inflammatory
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020901030A AU2020901030A0 (en) | 2020-04-02 | A method of treatment | |
| AU2020901030 | 2020-04-02 | ||
| AU2020902432A AU2020902432A0 (en) | 2020-07-14 | A method of treatment | |
| AU2020902432 | 2020-07-14 | ||
| AU2020903985 | 2020-11-02 | ||
| AU2020903985A AU2020903985A0 (en) | 2020-11-02 | A method of treatment | |
| AU2020904264 | 2020-11-18 | ||
| AU2020904264A AU2020904264A0 (en) | 2020-11-18 | A method of treatment | |
| AU2021900241A AU2021900241A0 (en) | 2021-02-03 | A method of treatment | |
| AU2021900241 | 2021-02-03 | ||
| AU2021900324 | 2021-02-10 | ||
| AU2021900324A AU2021900324A0 (en) | 2021-02-10 | A method of treatment | |
| PCT/AU2021/050226 WO2021195691A1 (en) | 2020-04-02 | 2021-03-15 | Methods and compositions for treating or preventing an inflammatory condition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3169702A1 true CA3169702A1 (en) | 2021-10-07 |
Family
ID=77926837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3169702A Pending CA3169702A1 (en) | 2020-04-02 | 2021-03-15 | Methods and compositions for treating or preventing an inflammatory condition |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230128114A1 (https=) |
| EP (1) | EP4125835A4 (https=) |
| JP (1) | JP2023521634A (https=) |
| AU (1) | AU2021250462A1 (https=) |
| CA (1) | CA3169702A1 (https=) |
| CO (1) | CO2022015048A2 (https=) |
| IL (1) | IL296943A (https=) |
| WO (1) | WO2021195691A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240325312A1 (en) * | 2021-07-15 | 2024-10-03 | Incannex Healthcare Limited | Composition comprising cannabidiol and hydroxychloroquine in a fixed dose combination capsule |
| WO2024025525A1 (en) * | 2022-07-27 | 2024-02-01 | Medterra Pharma Llc | Cannabinoid compositions and methods of using for the treatment of non-eosinophilic inflammation and inflammatory disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5453431A (en) * | 1993-10-29 | 1995-09-26 | Gilman; Andrew L. | Use of hydroxychloroquine for treatment of graft-versus-host disease |
| GB9807639D0 (en) * | 1998-04-14 | 1998-06-10 | Kennedy Rheumatology Inst | Anti-inflammatory agents |
| US20040242632A1 (en) * | 2001-11-09 | 2004-12-02 | Charous B. Lauren | Method for treating inflammatory bowel disease |
| US20200009077A1 (en) * | 2018-07-03 | 2020-01-09 | TRUETIVA, Inc. | Compositions for treating dermatological diseases |
| CN115916336A (zh) * | 2020-02-19 | 2023-04-04 | 施里玛·麦钱特 | 大麻二酚的组合物和治疗用途 |
-
2021
- 2021-03-15 US US17/907,322 patent/US20230128114A1/en active Pending
- 2021-03-15 AU AU2021250462A patent/AU2021250462A1/en active Pending
- 2021-03-15 IL IL296943A patent/IL296943A/en unknown
- 2021-03-15 JP JP2022559967A patent/JP2023521634A/ja active Pending
- 2021-03-15 EP EP21781628.9A patent/EP4125835A4/en active Pending
- 2021-03-15 WO PCT/AU2021/050226 patent/WO2021195691A1/en not_active Ceased
- 2021-03-15 CA CA3169702A patent/CA3169702A1/en active Pending
-
2022
- 2022-10-21 CO CONC2022/0015048A patent/CO2022015048A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021250462A1 (en) | 2022-12-01 |
| WO2021195691A1 (en) | 2021-10-07 |
| IL296943A (en) | 2022-12-01 |
| EP4125835A4 (en) | 2024-05-22 |
| JP2023521634A (ja) | 2023-05-25 |
| EP4125835A1 (en) | 2023-02-08 |
| CO2022015048A2 (es) | 2022-11-08 |
| US20230128114A1 (en) | 2023-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021507889A (ja) | ピラゾロピペリジン誘導体の新規な使用 | |
| KR102805246B1 (ko) | 수명 및 건강수명을 연장시키기 위한 제제 | |
| CN117338783A (zh) | 哌啶基-吲哚衍生物的用途 | |
| Ramasamy et al. | Avenanthramide-C restores impaired plasticity and cognition in Alzheimer’s disease model mice | |
| Bao et al. | Therapeutic effects of Chinese medicine Di-Long (Pheretima vulgaris) on rheumatoid arthritis through inhibiting NF-κB activation and regulating Th1/Th2 balance | |
| Park et al. | AMPK activation reduces vascular permeability and airway inflammation by regulating HIF/VEGFA pathway in a murine model of toluene diisocyanate-induced asthma | |
| TW201033182A (en) | Tetrahydrotriazine compounds for treating diseases associated with AMPK activity | |
| Wang et al. | Kynurenic acid ameliorates lipopolysaccharide-induced endometritis by regulating the GRP35/NF-κB signaling pathway | |
| CA3169702A1 (en) | Methods and compositions for treating or preventing an inflammatory condition | |
| Sha et al. | Hsp90 inhibitor HSP990 in very low dose upregulates EAAT2 and exerts potent antiepileptic activity | |
| Bharate et al. | Discovery and preclinical development of IIIM-160, a Bergenia ciliata-based anti-inflammatory and anti-arthritic botanical drug candidate | |
| US20230078820A1 (en) | Fenfluramine for treatment of demyelinating diseases and conditions | |
| Park et al. | Cilostazol protects mice against endotoxin shock and attenuates LPS-induced cytokine expression in RAW 264.7 macrophages via MAPK inhibition and NF-κB inactivation: Not involved in cAMP mechanisms | |
| RS67283B1 (sr) | Kombinovana terapija sa acetil-leucinom i miglustatom za lečenje bolesti lizozomskog skladištenja | |
| WO2024228949A1 (en) | Compositions for modulating the expression of aquaporins in diabetes and associated conditions | |
| KR20120047345A (ko) | Ｉｌ-6 활성 억제 작용을 갖는 화합물 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 ｉｌ-6로 매개되는 질환의 예방 또는 치료용 조성물 | |
| US20240325312A1 (en) | Composition comprising cannabidiol and hydroxychloroquine in a fixed dose combination capsule | |
| JP6708376B2 (ja) | ＩＦＮ−γ及び／又はＩＬ−１７の産生抑制剤、並びにＴｈ１細胞及び／又はＴｈ１７細胞の分化抑制剤 | |
| JP7249433B2 (ja) | 蜂毒抽出物を有効成分として含有する神経炎症疾患の予防または治療用組成物 | |
| Kim et al. | Anti-inflammatory effects of Portulaca oleracea L. on the LPS-induced RAW 264.7 cells | |
| US20240238299A1 (en) | Use of pyrrolopyrimidine compound | |
| US20260060949A1 (en) | Method for treating damage induced by sleep deprivation | |
| JP2002523362A (ja) | 喘息発病を予防するための方法 | |
| KR100581433B1 (ko) | 이뮤노글로블린 이 의존적 히스타민 방출 인자의 분비억제용 조성물 | |
| KR20250062979A (ko) | Taz 또는 이의 작용제를 유효성분으로 포함하는 염증성 피부질환 예방 또는 치료용 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250307 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250307 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250307 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250314 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250314 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250407 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250430 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250516 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260302 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260302 |